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Abstract
To characterize the HIV-2 integrase gene polymorphisms and the pathways to resistance of HIV-2 patients failing a
raltegravir-containing regimen, we studied 63 integrase strand transfer inhibitors (INSTI)-naı¨ve patients, and 10 heavily
pretreated patients exhibiting virological failure while receiving a salvage raltegravir-containing regimen. All patients were
infected by HIV-2 group A. 61.4% of the integrase residues were conserved, including the catalytic motif residues. No INSTI-
major resistance mutations were detected in the virus population from naı¨ve patients, but two amino acids that are
secondary resistance mutations to INSTIs in HIV-1 were observed. The 10 raltegravir-experienced patients exhibited
resistance mutations via three main genetic pathways: N155H, Q148R, and eventually E92Q - T97A. The 155 pathway was
preferentially used (7/10 patients). Other mutations associated to raltegravir resistance in HIV-1 were also observed in our
HIV-2 population (V151I and D232N), along with several novel mutations previously unreported. Data retrieved from this
study should help build a more robust HIV-2-specific algorithm for the genotypic interpretation of raltegravir resistance, and
contribute to improve the clinical monitoring of HIV-2-infected patients.
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Introduction
The Human Immunodeficiency Virus Type 2 (HIV-2) infects
1–2 million people worldwide, most of which in West Africa,
where it is endemic [1]. In Europe, Portugal is the country with
the highest frequency of HIV-2 infection, accounting for 543
(3.1%) of all AIDS cases [2]. Despite a slow progression of disease
in most infected people, 20–25% of HIV-2 patients progress to
AIDS if untreated [3,4].
The therapeutic options for HIV-2 patients are still limited. The
virus is naturally resistant to non-nucleoside reverse transcriptase
inhibitors (NNRTIs) [5,6] and to the fusion inhibitor enfuvirtide
(T-20) [6–8]. Compared to HIV-1, HIV-2 has reduced sensitivity
to some protease inhibitors (PIs) [9,10], a lower genetic barrier
towards resistance for most drugs [11–13], along with a faster
acquisition of resistance for some of them [12].
The recent pharmacological class of Integrase Strand Transfer
Inhibitors (INSTIs) represents a promising therapeutic option for
the treatment of HIV-2 infection. Integrase (IN) is a multi-domain
protein consisting of the N-terminal domain (NTD, HIV residues
1–49), catalytic core domain (CCD, residues 50–212), and C-
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terminal domain (CTD, residues 213–288). The NTD contains a
conserved HHCC Zn-coordination motif, and Zn-binding con-
tributes to IN multimerization and catalytic function [14,15]. The
CCD contains an invariant triad of acidic residues (Asp-64, Asp-
116, Glu-152 on HIV-1) that forms the enzyme active site [16–
18]. The CCD also contributes to IN multimerization [19] and
engages viral [20–22] and chromosomal [23,24] DNAs during
integration. The CTD, which is the least conserved of the domains
among retroviruses [25], also contributes to specific [26] and non-
specific [27–29] DNA interactions, as well as multimerization [30].
Despite a 40% difference in amino acid sequence between HIV-
1 and HIV-2 integrases, phenotypic assays carried out with
reference strains or clinical isolates have shown that all approved
inhibitors [i.e. raltegravir (RAL), elvitegravir (EVG) and dolute-
gravir (DTG)] are effective against HIV-2. In vitro studies have
shown that the HIV-1 and HIV-2 wild-type integrases have a
similar phenotypic susceptibility to INSTIs [31–34], probably due
to the 100% conservation of the catalytic triad DDE and the
HHCC and RKK motifs between the two viruses [33,35,36,36],
and that INSTIs exert a potent inhibitory effect on HIV-2
replication [33,37]. In vivo data has also revealed promising results:
raltegravir, the first INSTI to be licensed for clinical use, has been
used on some HIV-2 infected patients as part of their salvage
regimens with, at least, a good short term response concerning
suppression of plasma viral load and CD4 cell recovery [34,38–
40]. However, as for other antiviral drugs, resistance to RAL
emerges rapidly both in vitro and in vivo, greatly reducing the
susceptibility of the virus to the inhibitor. The specific amino acid
changes that are known to confer RAL resistance in HIV-1 have
also been shown to develop in RAL-treated HIV-2 patients:
N155H, Q148K/R and, to a lesser extent, Y143C [39,41–46].
Overall, three major resistance pathways have been identified and
shown to elicit high-level raltegravir and elvitegravir resistance in
HIV-2: i) N155H/E92Q, ii) Q148R/G140S, and iii) Y143C/
E92Q or Y143C/T97A [42,47,48]. On the other hand, the
N155H-Y143C and N155H-Q148R replacements seem to define
mutually exclusive pathways to RAL resistance in HIV-2 [32,42].
RAL and EVG show extensive cross-resistance in HIV-2, as in
HIV-1 [43,46,49,50], but DTG retains activity against some RAL
and EVG-resistant HIV-1 strains, both in vitro and in vivo [51–53].
Information on its efficiency against HIV-2 strains bearing
integrase inhibitor resistance mutations is still limited, but
phenotypic assays carried out with HIV-2 clinical isolates from
patients treated with RAL showed that mutations T97A/Y143C,
G140S/Q148R or G140T/Q148R/N155H conferred moderate
resistance to DTG (7–18-fold increase of the EC50) [37]. As in
HIV-1 the association T97A/Y143C does not confer resistance to
DTG, extreme caution must be taken when extrapolating HIV-1
knowledge to HIV-2. Corroborating this is the fact that, at this
time, it is still unknown whether the combination H51Y/R263K,
that confers some level of resistance to DTG in HIV-1 [54,55],
could be relevant as a mutational pathway leading to HIV-2
resistance.
Overall, HIV-2 resistance pathways to INSTIs are still poorly
characterized. So the aims of this study were i) to investigate the
natural polymorphism of the HIV-2 integrase gene, and ii) to
further characterize the genotypic resistance profiles of HIV-2
patients failing RAL-containing regimens.
Materials and Methods
Study design and sequences
This study assessed 73 HIV-2 group A infected patients followed
at different hospitals mainly in the central and southern areas of
Portugal. The HIV-2 group was determined using the Rega
Subtyping Tool v2.0. 63 patients were RAL-naı¨ve, and constituted
the control group. 23/63 had been previously exposed to
antiretroviral (ARV) therapy: 21 had received nucleoside/nucle-
otide reverse transcriptase inhibitors (NRTIs) and protease
inhibitors (PIs), one had received NRTIs and non-nucleoside
reverse transcriptase inhibitors (NNRTIs), and one had received
NRTIs, NNRTIs and PIs. The remaining 40/63 patients had
never been exposed to antiretroviral drugs at the time the sample
was obtained. Ten patients were heavily pretreated and were on a
salvage RAL-containing regimen. All the longitudinal genotypic
resistance data available for these patients, pre- and during RAL
exposure, was considered for analysis, in a total of 20 sequences.
For statistical purposes, only one genotype, corresponding to the
most recent isolate of each patient, was considered.
Mutations were defined as differences at the amino acid level
from the wild-type reference sequence (HIV2_ROD_M15390),
including those that were present as part of a nucleotide mixture.
Despite not being a primary isolate, HIV-2_ROD can be
considered a reference control isolate for this study because its
susceptibility to INSTIs has been previously demonstrated [33].
The sequences obtained from RAL-naı¨ve patients were used to
uncover natural polymorphisms, and to determine whether the
critical amino acid substitutions associated with resistance to
INSTIs in HIV-1 are naturally present in HIV-2. An amino acid
position was considered polymorphic when at least two different
amino acids were found [56]. Amino acids not mutated were
defined as conserved. Amino acid variability at a given position
was established by calculating the percentage of sequences
harboring an amino acid different from the HIV2_ROD_M15390
reference sequence. The most polymorphic positions were
considered to be those where more than 30% of sequences in
the control group were variable, according to the criterion
previously defined by others [56].
Mutations were considered as being selected by therapy if
absent from RAL-naı¨ve sequences and present in $1 sequences
from RAL-treated individuals. All the amino acid variants
occurring at non-polymorphic HIV-2 integrase positions, i.e.,
occurring only in RAL-treated individuals, were analyzed. We also
investigated the occurrence at such positions of major and
compensatory drug resistance mutations already associated with
in vivo or in vitro resistance to INSTIs in HIV-1 [according to
Lataillade M et al. 2007 [35] and to the 2013 Update of the Drug
Resistance Mutations in HIV-1 [57]] or in HIV-2 [according to
the Algorithm for the Interpretation of Genotypic HIV-2
Resistance Data (http://regaweb.med.kuleuven.be/sites/default/
files/algorithms/Rega_HIV2_Rules_v8.0.2.pdf) [58]].
HIV-2 integrase sequencing
The integrase coding region of the pol gene was amplified and
sequenced from plasma samples of the HIV-2 infected patients, in
a total of 293 amino acids analyzed. Viral RNA was extracted
from 1 ml of plasma according to Biome´rieux’s easyMAG automatic
extraction procedure, and used to amplify and sequence the last
domain of the pol gene, comprising the integrase. To do so, the
protocol described at Bercoff DP et al. [36] was used, but some
adjustments were made. 10–15 ml of RNA were initially subjected
to 5 min at 70uC followed by 5 min on ice to avoid the generation
of possible intramolecular base-pairings in single-stranded RNAs.
RNA was then retrotranscribed using Super SuperScript III One-Step
RT-PCR System with Platinum Taq DNA Polymerase (Invitrogen Life
Technologies) in a 50 ml mix containing 10 mM of each forward
primer JR25 and reverse primer JR47 (Table 1). Cycling
conditions consisted of reverse transcription at 45uC for 1 h,
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denaturation at 94uC for 2 min followed by 40 amplification cycles
of 94uC for 30 sec, 53uC for 45 sec and 72uC for 1 min 45 sec,
and a final elongation step at 72uC for 3 min. A nested PCR was
then performed with 2 ml of the previously amplified cDNA, using
AmpliTaq Gold DNA Polymerase (Applied Biosystems) with 10 mM
of each forward primer H2Mp9 and reverse primer JR46
(Table 1). Nested PCR conditions consisted of denaturation at
95uC for 10 min, 40 amplification cycles of 94uC for 30 sec, 50uC
for 45 sec and 72uC for 1 min 30 sec, and a final elongation step
at 72uC for 10 min. Amplification products were checked on a 2%
agarose gel with ethidium bromide and 8 mL of GeneRuler DNA
Ladder Mix (Fermentas) for reference, and were subsequently
purified through the YM-100 Microconcentrators Method ac-
cording to the ViroSeq HIV-1 Genotyping System v2.0 Protocol (Abbott).
Dilution adjustments of the PCR products were made when
necessary. The sequencing reaction was then performed using the
Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and
primers H2Mp9, JR44, JR45, AV33 (forward), JR46 and JR48
(reverse) (Table 1). Cycling conditions consisted of 30 amplifica-
tion cycles of 10 sec at 96uC, 5 sec at 50uC and 4 min at 60uC.
Products were purified and run on an ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems). Nucleotide sequences were aligned
against the HIV-2 ROD reference strain (GenBank accession #
M15390), and edited with SeqScape Software Version 2.5 (Applied
Biosystems).
GenBank accession numbers
All the newly determined nucleotide data were deposited in
GenBank under the following accession numbers: KF859774 -
KF859846, and KF951329-KF951338.
Statistical analysis
For the determination of which mutations are selected in HIV-2
as a response to RAL pressure, sequences of 63 RAL-naı¨ve and 10
RAL-experienced patients were used, and the prevalence of
different amino acids at every codon position was estimated. To do
so, the different amino acids occurring at each integrase position
were weighted according to the following criterion: when the
amino acid was different from that of the reference sequence, it
was counted; when the amino acid was the same as the reference
sequence, it was not. In case of double and triple populations, only
the mutant amino acids were taken into account when counting:
each was given the same weight so that the sum of all mutant
amino acids at each position would be 1. This was computed by
alignment of nucleotide sequences and HIV2_ROD strain with
Muscle [59], manual edition with JalView version 2 [60], and
writing of the scripts with Python Programming Language (http://
www.python.org/) [61]. All integrase positions were compared to
the HIV2_ROD_M15390 sequence.
INSTI-naı¨ve patients were further subdivided into a group of
ARV-naı¨ve patients and a group of previously ARV (NRTI/PI) -
experienced patients, for the purpose of comparing the prevalence
of mutated amino acids between both groups. To do so, a x2 test
(based on a 262 contingency table containing the numbers of
isolates from untreated and treated persons, and the number of
isolates with and without mutations) was computed in R v.2.15.2,
and a p-value,0.05 was considered statistically significant.
Shannon’s entropy at each position of INSTI-naı¨ve sequences, a
measure of the amount of information contained at that position,
was calculated using the Los Alamos Database sequence Entropy
website http://www.hiv.lanl.gov/content/sequence/ENTROPY/
entropy_one.html for group A strains.
Ethics Statement
Due to the fact that this is a retrospective study, and that all the
procedures were standard of care – e.g., no extra blood collections
were performed for study procedures, all the samples being surplus
from collections taken for clinical monitoring – the Ethical
Committee of Centro Hospitalar de Lisboa Ocidental did not
consider to be necessary to obtain written informed consent from
patients.
This study received ethical approval by the Ethical Committee
of Centro Hospitalar de Lisboa Ocidental (Reference no. 96/
CES-2013).
Results
In the present study, we assessed a total of 83 HIV-2 integrase
sequences, which, to our knowledge, represents the most extensive
analysis performed to date of the integrase coding region of HIV-
2. All the sequences belong to HIV-2 group A. 63 sequences
belong to 63 RAL-naı¨ve patients, and 20 sequences belong to 10
heavily pretreated HIV-2 infected patients with virological failure
while receiving a salvage raltegravir-containing regimen (Table 2).
Analysis of HIV-2 integrase gene polymorphisms
We analyzed 63 integrase sequences retrieved from RAL-naı¨ve
patients. At the time of integrase genotyping, 40 patients were
antiretroviral (ART)-naı¨ve, 22 patients were receiving NRTI+PI-
based regimens, and one patient was receiving an NRTI+NNRTI-
based regimen, despite the widely recognized inefficacy of
NNRTIs on HIV-2. We report IN polymorphisms for this group
of patients with respect to the reference sequence ROD (Table 2).
Table 1. HIV-2 integrase primers given with their positions in HIV-2 ROD indicated in parenthesis. (+, sense; 2, antisense).
Primer Nucleotide sequence Nucleotides Reference
JR25 [+2528] 59-GCA CCT CCA ACT AAT CCT-39 18 Bercoff DP et al. 2010 [36]
JR44 [+3689] 59-GAG ACC TTC TAC ACA GAT GG-39 20 Bercoff DP et al. 2010 [36]
JR45 [+3971] 59-TAT GTT GCA TGG GTC CCA GC-39 20 Bercoff DP et al. 2010 [36]
JR46 [25019] 59-ATG CCC ATC CCA CCT TAT GGT G-39 22 Bercoff DP et al. 2010 [36]
JR47 [25041] 59-ATT ACC CTG CTG CAA CTG CAC C-39 22 Bercoff DP et al. 2010 [36]
JR48 [24466] 59-GTT CTA TAC CTA TCC ACC-39 18 Bercoff DP et al. 2010 [36]
AV33 [+4433] 59-GTG AAG ATG GTA GCA TGG TGG-39 21 Bercoff DP et al. 2010 [36]
H2Mp9 [+2932] 59-GGA TGA TAT CTT AAT AGC TAG-39 21 Colson P et al. 2004 [56]
doi:10.1371/journal.pone.0092747.t001
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Table 2. HIV-2 group A IN polymorphisms.
Position ROD Shannon entropy RAL-naı¨ve patients (63 sequences)
30–50% N-terminal Domain HHCC Zinc coordination finger L2 0.824 I (19%)
51–70% K4 0.803 N (1%), S (1%), R (24%)
71–90% Y15 0.571 F (10%)
V19 1.058 I (29%), M (8%)
K20 0.665 Q (10%), R (3%)
S23 1.037 A (8%), C (10%), T (3%)
I28 0.991 M (1%), L (50%)
N30 1.279 K (60%), M (2%), L (2%), Q (13%), T (6%)
L31 0.554 I (5%)
V32 0.373 I (2%)
R34 0.780 K (14%)
S39 0.533 T (92%)
A41 1.075 G (2%), N (2%), P (14%), T (17%)
A49 0.266 P (2%)
Catalytic Core Domain (with DDE Catalytic Triad) I50 0.682 M (5%), T (8%), V (5%)
(*) H51 0.079 Q (2%)
N55 0.308 D (10%)
E57 0.493 A (2%), D (8%)
L58 0.923 F (2%), I (8%), V (8%)
T60 0.651 A (1%), I (9%), M (2%), V (3%)
E69 0.373 D (2%)
(*) I72 0.980 V (40%)
(*) I84 0.266 V (6%)
E87 0.137 K (2%)
S93 0.937 T (57%)
R95 0.576 K (2%)
Q96 0.349 H (6%), Y (2%)
L101 0.308 I (2%)
S106 0.349 G (2%)
I110 0.079 V (2%)
T111 0.137 R (2%)
L113 0.531 V (2%)
H114 0.231 Q (2%)
A119 0.536 D (2%), G (2%), P (8%), R (1%)
T122 0.231 I (2%), M (1%), V (1%)
Q124 0.450 H (2%)
(*) E125 0.386 D (2%)
V129 0.216 A (2%)
I133 1.104 A (2%), T (3%), V (74%)
(*) S138 0.582 T (19%)
V141 0.386 I (2%)
(*) A153 0.274 S (3%)
(*) H156 0.388 L (2%), P (2%), R (2%)
(*) H157 0.310 P (2%)
(*) S163 0.913 D (21%), G (1%), N (7%)
R164 0.406 K (10%)
E167 0.921 D (41%)
N170 0.464 E (2%), I (2%)
I172 1.056 M (10%), V (65%)
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Table 2. Cont.
Position ROD Shannon entropy RAL-naı¨ve patients (63 sequences)
E173 0.310 K (2%)
(*) I175 0.531 L (2%), V (17%)
L177 0.450 V (2%)
M178 0.159 I (2%), R (2%)
I180 0.773 A (6%), T (5%), V (78%)
H181 0.079 Y (2%)
C182 0.079 Y (2%)
R188 0.079 W (2%)
G189 0.079 E (2%)
G190 0.079 E (2%)
S197 0.781 A (65%)
L200 0.464 F (2%), V (2%)
(*) I201 0.386 T (2%), V (2%)
(*)T206 0.895 A (41%), S (2%)
E207 0.137 D (3%)
I210 0.266 V (6%)
F212 0.271 L (2%)
C-terminal Domain F213 0.187 F (5%)
Q214 0.454 H (10%)
A215 0.788 N (2%), S (10%), T (11%)
K216 0.079 R (2%)
D217 0.216 D (2%), K (2%)
S218 0.476 L (13%)
K219 0.374 E (2%), N (2%), R (5%)
L220 0.629 F (33%)
K221 0.608 Q (19%), R (2%)
N222 0.419 K (11%)
R224 0.231 Q (6%)
F227 0.079 Y (2%)
R228 0.079 K (2%)
E229 0.137 K (2%)
Q233 0.079 H (2%)
L234 0.080 Q (2%)
W235 0.079 S (2%)
E240 0.688 D (2%), K (3%), Q (2%)
L241 0.159 H (2%)
E246 0.713 D (33%)
(*) V249 0.295 I (5%)
L250 0.556 I (87%), V (1%)
V251 0.349 A (8%)
T255 0.744 A (27%)
D256 0.680 E (11%)
I259 0.870 V (59%)
I260 0.949 M (1%), V (52%)
I267 0.310 V (2%)
I268 0.216 V (3%)
R269 0.940 K (33%)
R274 0.388 K (2%)
Q275 0.159 K (2%)
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From a total of 293 integrase codons analyzed, 61.4% (180/
293) were non-polymorphic and 38.6% (113/293) were naturally
polymorphic. Of the 113 variable positions, 39 (34%) were
mutated at least twice (Table 2). The catalytic triad DDE, the
zinc coordination motif HHCC, and the RKK motif, at positions
64, 116 and 152 (DDE), 12, 16, 40 and 43 (HHCC), and 231, 258
and 264 (RKK), respectively, were completely conserved in our
dataset, and the CTD was the least conserved of the three
domains, as foreseeable. The most polymorphic positions were
located at 23 HIV-2 group A IN positions: 19, 28, 30, 39, 41, 72,
93, 133, 167, 172, 180, 197, 206, 220, 246, 250, 259, 260, 269,
277, 281, 286 and 292 (Table 2).
Integrase sequences from RAL-naı¨ve patients were further
examined to determine whether the critical amino acid substitu-
tions associated with in vivo and in vitro INSTIs resistance in HIV-1
[35,57] occur as baseline polymorphisms in HIV-2. None of the
primary mutations at positions 66, 92, 143, 147, 148 and 155
responsible for RAL or EVG resistance in HIV-1 were detected in
sequences from HIV-2 RAL-naı¨ve patients. However, two
secondary mutations corresponding to resistance-associated sub-
stitutions in HIV-1 were observed: 206S and 249I. The most
common resistance associated residue was 249I, present in 5% of
sequences from the control group, while 206S was present in 2%
of these sequences. In this group of patients we also detected
polymorphisms at 8 additional positions associated with INSTIs
resistance in HIV-1: 125D, 138T, 153S, 156L/P/R, 157P, 163D/
G/N, 201T/V and 280S. In these patients, we further observed
two amino acid changes that were previously described as
secondary mutations in the HIV-2 IN, I84V and S163G/D
[44,45], and two polymorphisms at positions previously associated
with HIV-2 INSTIs resistance: H51Q, I175L/V [36,44,46].
To evaluate whether specific drug pressure induced by antiviral
drugs different from INSTIs, in particular NRTIs, may also select
or induce mutations in the HIV-2 IN gene, the different
prevalence of IN mutations between the two populations of
INSTI-naı¨ve patients (drug naı¨ve and NRTI/PI treated) was
investigated. Overall variability within IN was higher in treatment-
naı¨ve (34.5%) than in NRTI/PI-experienced patients (23.9%), and
this difference reached statistical significance (x2 = 7.43;
p = 0.00641). When analyzing each polymorphism individually,
we observed that two polymorphisms showed a significant increase
in prevalence in HIV-2 NRTI/PI-treated patients compared with
ARV naı¨ve patients: V19M (n = 4/23 vs. n = 1/40; p = 0.0353)
and L58V (n = 4/23 vs. n = 1/40; p = 0.0353). Interestingly, and
unlike the above-mentioned mutations, other two IN polymor-
phisms showed a significant decrease in prevalence in isolates from
NRTI/PI-treated patients, as compared with drug-naı¨ve patients,
thus suggesting a negative association with NRTI/PI treatment:
E246D (n = 11/23 vs. n = 31/40; p = 0.0162) and M277L (n = 6/
23 vs. n = 21/40; p = 0.0412).
Analysis of HIV-2 integrase gene mutations potentially
associated with RAL resistance
Ten heavily pretreated HIV-2 infected patients exhibiting
incomplete viral suppression or virological rebound while receiv-
ing a salvage raltegravir-containing regimen were investigated. Six
patients had only one isolate for analysis, and the other four
patients had longitudinal genotypic data. In these four patients,
RAL was kept despite a detectable viral load, because there were
no alternatives to the current regimen. The median time of
exposure to RAL was 17 months (range: 8–35 months). When the
drug resistance testing was performed, nine patients were receiving
different combinations of NRTI+PI, and one patient was receiving
only NRTI-based therapy, in addition to RAL. All had previously
received several combinations of NRTIs and PIs (Table 3).
RAL resistance associated mutations were identified in the ten
patients: one displayed the 148 pathway, seven displayed the 155
pathway, and two displayed none of the major RAL resistance
mutations, but instead the E92Q - T97A motif (patients 9 and 10,
Table 3). No switch of resistance pathway from the 155 to the 148
or 143 pathways was observed.
Our analysis identified 19 amino acid substitutions selected in
RAL-treated patients at some time point during longitudinal
follow-up, and potentially emerging as secondary response to RAL
Table 2. Cont.
Position ROD Shannon entropy RAL-naı¨ve patients (63 sequences)
E276 0.344 G (2%)
M277 1.090 L (43%), V (6%)
D278 0.159 G (2%)
S279 0.431 C (2%), N (5%)
(*) G280 0.680 S (19%)
S281 0.906 P (41%)
H282 0.597 N (12%), R (2%)
L283 0.630 V (8%)
G285 0.431 D (2%), S (5%)
A286 0.879 T (30%)
D289 0.466 N (8%), T (2%)
E291 0.349 G (2%)
M292 0.791 V (73%)
Polymorphisms of the HIV-2 group A IN sequences from 63 treatment-naı¨ve patients are reported with respect to the ROD reference sequence. The three different
domains of IN are indicated: the N-terminal domain (AA 1–49); the catalytic core domain (AA 50–212) containing the conserved catalytic triad (DDE motif); and the C-
terminal domain (AA 213–288). Positions known to confer resistance to INSTIs in HIV-1 or HIV-2 are marked with a star (*). The frequency (percentage) of each of each of
the polymorphisms is indicated in brackets. Only positions where variations were detected are reported. Shannon’s entropy at each variable position is indicated; an
entropy value of 0 corresponds to an amino acid strictly conserved, and higher entropy values indicate more variability.
doi:10.1371/journal.pone.0092747.t002
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pressure (Table 3, Figure 1). Fifteen amino acid substitutions
occurred at non-polymorphic positions of HIV-2 wild-type: Q44H
(n = 2 patients), Q45H (n = 1), K46R (n = 3), K71R (n = 1), E85K
(n = 1), Q91R (n = 1), E92A/G/Q (n = 8), T97A (n = 4), K127R
(n = 1), Q148R (n = 1), V151I (n = 1), N155H (n = 7), N160K
(n = 2), D232N (n = 1) and K236T (n = 1). Four amino acid
substitutions occurred at naturally polymorphic HIV-2 positions,
but were considered in our analysis because they were previously
reported as resistance associated mutations in integrase sequences
from RAL-treated HIV-2 patients: I84V (n = 4), A153G (n = 3),
H157N/S/R (n = 1) and S163D (n = 1). Substitutions E92A/G/
Q, T97A, Q148R, A153G and N155H have been previously
associated with some level of resistance to RAL on HIV-2.
Substitutions E92Q, T97A, Q148R, V151I, N155H and D232N
have been previously associated with INSTIs resistance in HIV-1.
The ‘148 pathway’ was observed in the virus from one patient
through the presence of Q148R (patient 1, Table 3). No accessory
mutations were detected. Mutation Q148H, the most frequently
observed in HIV-1 at this position, was not present in our dataset.
The HIV-1 signature mutation N155H was observed in viruses
from seven patients. Four of these patients had only one genotype
available for analysis, and three patients had longitudinal
genotypic data while still under RAL. Of the four patients with
only one post-RAL genotype, two shared the same pattern of
accessory mutations, I84V - E92A - A153G (patients 2 and 5,
Table 3); one displayed only two of these mutations, I84V -
A153G (patient 3, Table 3), probably due to the short exposure
time to RAL; and the other displayed E92Q - T97A - S163D
(patient 4, Table 3). Besides these accessory mutations previously
described in HIV-2, viruses from these four patients also displayed
amino acid substitutions in six HIV-2 non-polymorphic sites:
Q44H (n = 2), Q45H (n = 1), K71R (n = 1), K127R (n = 1),
D232N (n = 1) and K236T (n = 1), all previously unreported in
HIV-2. The three patients with longitudinal genotypic data
(patients 6, 7 and 8, Table 3) allowed us to investigate the
evolution of HIV-2 integrase genotypic resistance profiles under
continued RAL selective pressure. They all harbored the N155H
mutation in association with E92Q in two cases (patients 6 and 7,
Table 3), and with E92G in one other case (patient 8, Table 3).
Viruses from these patients also selected the I84V substitution in
one case (patient 6, Table 3), N160K in two cases (patients 7 and
8, Table 3), H157N/S/R in one case (patient 6, Table 3), and
T97A in viruses from one of the patients who selected E92Q
(patient 7, Table 3). In this last patient, we could see the initial
selection of Q91R, its replacement by E92Q three months later,
followed by the selection of T97A - N160K along with E92Q and
the concurrent selection against mutation at position N155. Four
substitutions at non-polymorphic HIV-2 positions were also
observed in these patients’ genotypes at some point during RAL
selective pressure: K46R (n = 3), V151I (n = 1), L242P (n = 1) and
D232N (n = 1). From all the substitutions here reported for the first
time, and whose impact on RAL resistance is still unknown, K46R
was clearly selected and maintained over time in these patients’
viruses. The remaining substitutions were observed as single
episodes in patients without longitudinal genotypic data, or were
deselected over time in patients with longitudinal data (Table 3).
Collectively, our data revealed three distinct patterns of
mutations eliciting resistance to raltegravir in HIV-2: Q148R in
one patient, E92Q - T97A in two patients, and N155H - E92A/
G/Q in six patients. The last patient (whose viruses selected
N155H - I84V - A153G) was genotyped early in RAL failure, and
we cannot exclude that that pattern of mutations will evolve to one
of the previously referred patterns as the exposure time to RAL
increases.
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Discussion
Studies assessing the development of resistance to raltegravir in
HIV-2 infection are relatively scarce and limited in sample size.
This is the first study to investigate the integrase genomic region of
HIV-2 using a comprehensive number of HIV-2 clinical samples:
83 integrase sequences from 73 HIV-2 infected patients.
HIV-2 integrase gene polymorphism
The overall rate of amino acid variation was 38.6% relatively to
the HIV-2 ROD reference strain, which is a value slightly higher
than the one reported by other, smaller scale, studies, where values
around 27% [31], 33.1% [36], and 38% [33] have been described.
This is probably related to the largest size of our sample. This
variability is similar to the one reported for the HIV-1 integrase,
where 37.5% [62] and 38.2% [63] of sequence variability has been
observed for IN residues. The catalytic motif residues were
completely conserved in our dataset, in line with what was
expected in face of their essential nature for IN function [64–66].
The low variability tolerated at such positions agrees with what
other authors have previously described [31,33,36] and confirms
the crucial role of these amino acids in IN efficacy and viral
replication.
In our RAL-naı¨ve data we found no evidence of the primary
mutations responsible for raltegravir or elvitegravir resistance in
HIV-1 or HIV-2. However, two amino acid substitutions at
positions implicated in HIV-1 secondary resistance to raltegravir
or elvitegravir were naturally present in the sequences from these
patients. Amino acid 249I had already been observed in the HIV-
2 integrase by previous authors [33,36,67], but 206S is here
reported for the first time. Furthermore, at 8 HIV-1 resistance
associated positions we observed atypical amino acid substitutions
(125D, 138T, 153S, 156L/P/R, 157P, 163D/G/N, 201T/V and
280S), some of which had been previously referred by others [31].
However, their full impact on HIV-2 resistance remains to be
elucidated.
In our sequences from INSTI-naı¨ve patients, we observed that
some polymorphisms changed their prevalence according to prior
ARV (NRTI/PI) exposure: V19M and L58V significantly
increased their frequency in NRTI/PI-treated patients, while
E246D and M277L significantly decreased their frequency in this
group. Indeed, IN and RT are thought to interact [66]. In HIV-1,
recent studies have shown that some IN polymorphisms change
their prevalence according to prior NRTI exposure [63], and that
there are some associations between IN mutations and RT
resistance mutations in ARV-failing patients [68,69]. This
supports the hypothesis of a tight physical interaction between
the viral IN and RT, and/or a potential co-evolution of some of
their mutations [70].
The mechanisms of this observed difference in the prevalence of
some IN polymorphisms between drug-naı¨ve and ARV-treated
patient populations, as well as the associations between specific IN
and RT mutations, needs further investigation. Since the coding
regions for PR, RT and IN are located in the same gene, and the
three enzymes before maturation are folded together in a unique
polyprotein precursor, it is conceivable that several structural
interactions (also among the three different proteins) may occur at
this level [63]. Furthermore, the end-product of the RT-catalysed
reaction is the substrate for IN. It is also conceivable that IN
mutations can appear under specific drug pressure induced by
antiviral agents such as NRTIs, in order to rescue the correct
binding between the RT and IN enzymes, impaired by emergence
of drug resistance mutations. In addition, it is possible that IN
polymorphisms are co-selected with RT resistance mutations for
viral fitness compensatory rescue, or vice versa.
HIV-2 integrase gene mutations potentially associated
with RAL resistance
In the present study, of the HIV-1 RAL signature mutations
already described in HIV-2, only N155H and Q148R were
observed. Treatment failure of HIV-2 RAL regimens seems to be
associated with the emergence of resistance mutations via two
main resistance pathways, stemming from N155H and Q148R. In
the two patients who did not select any of these, we only observed
E92Q - T97A mutations. Since in one case we observed a de-
selection of the N155H mutation under therapy in a compliant
patient, we can speculate that this might be a late stage evolution
of the N155H pathway. In our dataset, this pathway seems to be
the preferential towards the development of RAL resistance in
HIV-2 group A viruses, since N155H was the predominant
mutation selected in these patients, clearly outnumbering Q148R
which was observed only in one patient. This disagrees with what
others have reported about the N155H pathway being observed
only in patients infected with HIV-2 group B viruses [41].
In addition to these two major (Q148R and N155H) and two
minor (E92Q and T97A) RAL resistance mutations, other minor
mutations also associated with RAL resistance in HIV-1 were
observed in HIV-2 patients failing RAL-containing regimens
(V151I and D232N), along with several novel mutations previously
unreported in HIV-1 or HIV-2.
In line with previous reports, the A153G substitution was always
detected in the same genotype as N155H, indicating a preferential
association with the 155 mutational pathway, and suggesting that
this double mutation may confer higher levels of resistance to RAL
than the N155H single mutant [44–46]. The Q91R substitution
was detected in a N155H carrying genotype. To our knowledge,
this is the first time that Q91R is associated with the 155 pathway
in HIV-2. To date, this mutation has rarely been reported, and,
when so, it was either associated with the 143 pathway, together
with T97A [46], or associated with the recently described
mutation I175M and conferring high levels of resistance to RAL
in vitro [36]. Further studies are necessary to elucidate the
individual impact of Q91R on HIV-2 resistance to RAL, and on
the replicative capacity of the virus.
Several atypical amino acid substitutions were selected in the
patients failing RAL. The majority was observed as single episodes
in patients without longitudinal genotypic data, or deselected over
time in patients with longitudinal follow-up. Mutation K46R,
however, was selected in patients with longitudinal data and
persisted, being apparently fixated in the virus genome. K46R was
always selected in N155H-carrying genotypes, and may constitute
a secondary mutation specific to the 155 resistance pathway in
HIV-2.
For HIV-2 patients remaining on a failing RAL regimen, and
for whom genotypic resistance follow-up was available, we could
distinguish one of two patterns: either an accumulation of
secondary RAL resistance mutations, or the replacement of pre-
selected mutations by novel variants. The former was more
common, being observed in two of the three patients with
longitudinal follow-up (patients 6 and 8, Table 3). Such
accumulation of mutations probably intends to overcome the
fitness costs due to the acquisition of primary mutations. Patient 7,
however, evidenced a different genotypic pattern of evolution,
through the replacement of pre-selected variants by novel ones. In
this patient, we could see the initial selection of N155H - Q91R,
followed by the replacement of Q91R by E92Q and K46R, and
later by the addition of T97A and N160K, with the simultaneous
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selection against mutation at position N155. This patient
constitutes an interesting case for several reasons: it was the only
patient where we could observe the replacement of pre-existing
mutations by new ones; it was the first time that Q91R, a mutation
never reported in HIV-1, was associated with the 155 pathway;
and it was the only case where we could see the selection against
major mutation N155H, albeit still under RAL pressure, and its
replacement with T97A - N160K. Viruses from the remaining
patients that selected the N155H mutation maintained it over
time, as previously described by others [44]. The patient in
question is reported as adherent to the therapy (adherence
evaluated by self-reporting and pill count), making unlikely the
hypothesis that this de-selection could be the result of incomplete
adherence. Furthermore, the de-selection of N155H occurs after
the longest exposure to raltegravir (35 months) in our dataset,
suggesting that despite the high level of RAL resistance conferred
by this mutation [44], the impairment it causes in viral replication
may lead to its replacement by other substitutions that allow a
more efficient trade-off between acquisition of resistance and
fitness costs. Therefore, we can speculate that the accumulation of
mutations E92Q, T97A and, eventually, K46R and N160K in this
patient may be sufficient to ensure resistance to RAL without the
fitness costs incurred by mutation N155H [71].
In the patients with longitudinal follow-up, no switch of
resistance profile from 155 to 148 or to 143 occurred. But
disparate observations have been made on this matter by different
HIV-2 study groups: one group agreed with our results and
reported no switch of genotypic resistance profiles in the HIV-2 IN
[41], but another group reported the switch from the N155H to
the Y143C resistance pathway by both population and clonal
sequencing [46]. This shift of resistance pathways is well
documented in HIV-1 [72,73], but further studies are required
to elucidate its occurrence in HIV-2. On the other hand, our data
corroborate what has been described both in HIV-1 [35,73] and
HIV-2 [32,42] reporting that the main pathways of RAL
resistance are mutually exclusive, since two primary resistance
changes were never observed in the same genotype.
Mutation Q148H, the most frequently observed in HIV-1 at
this residue was not detected in our dataset. Instead, we found
Q148R, which is sufficient to induce phenotypic HIV-2 RAL
resistance by itself [32,42]. Mutation G140S, usually selected with
Q148R to mitigate the fitness costs incurred by this primary
mutation [37,41,42,74], was not observed in our study, probably
due to the short exposure time of the patient to RAL (only 5
months).
E92Q was observed in our dataset either in association with
N155H, or with T97A. It is known that this secondary mutation
increases the level of resistance to RAL of HIV-2 mutants in a
Y143C- or N155H-resistant background, playing a more impor-
tant role in the HIV-2 than in the HIV-1 context [41,42,46]. In
two other patients, viruses selected and maintained the E92Q -
T97A pattern without any major mutation. One of these patients
is reported to have good adherence to therapy, and no adherence
data is available for the other patient. This seems to suggest that
E92Q, coupled with T97A, may be sufficient to elicit resistance to
RAL in HIV-2, albeit to a lesser extent than N155H or Q148R, as
previously demonstrated in vitro in the HIV-1 IN [75]. But it may
also be a late stage evolution of the N155H pathway. Also the
possibility of an incomplete adherence to therapy cannot be
formally excluded, since we cannot detect this bias with the self-
reporting method used with these two patients.
Besides E92Q, we also found two other substitutions at residue
E92: E92A, a mutation less frequently described at this residue
[41,42], was observed at two of the N155H-mutated viruses but,
similarly to what happens with T97A, apparently provides no
additional resistance to the virus [42]; and the atypical substitution
E92G was observed once in association with the N155H pathway,
as previously documented [42,46]. Both E92A (GCA) and E92G
(GGA) are not transitional amino acids from the wild-type E92
(GAA) to E92Q [CA(A/G)], as we confirmed through the analysis
of their nucleotide sequences, so we can speculate that these can be
true resistance mutations. However, phenotypic studies are
required to confirm this hypothesis.
Figure 1. Positions selected in vivo under RAL pressure in an HIV-2 integrase 3D model. 3D structure of HIV-2 integrase, modelled from
the Prototype Foamy Virus (PDB ID 3L2V), shown in complex with raltegravir (colored red) and DNA (colored purple). The 19 residues identified in this
study as potentially associated with RAL resistance are highlighted: residues involved in major RAL resistance pathways are colored blue (92, 97, 148
and 155), and residues corresponding to minor RAL resistance mutations are colored green (44, 45, 46, 71, 84, 85, 91, 127, 151, 153, 157, 160, 163, 232
and 236). For comparison, HIV-1 active site codon positions are colored red (64, 116 and 152). The 3D structure was adapted from the pdf entry 3L2V
using the JMol software (Available: http://www.jmol.org/).
doi:10.1371/journal.pone.0092747.g001
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T97A was always selected in E92Q-carrying viruses, once also
with N155H. The T97A - N155H association has been previously
reported in HIV-2 [41]. A recent study suggested that T97A
provides no additional resistance to viruses carrying the N155H
mutation, but may improve the fitness of enzymes that would
otherwise be catalytically impaired [42]. Our results suggest that
T97A may have the same role in viruses carrying the E92Q
mutation, although further studies are necessary to confirm this
hypothesis.
Conclusions
In conclusion, raltegravir is highly effective, but so far there is
no data to allow a recommendation on when to use this compound
in the context of HIV-2 infection, for a first-line or later regimen.
Taken together, data retrieved from this study should help build a
more robust HIV-2-specific algorithm for the genotypic interpre-
tation of raltegravir resistance. Nevertheless, further studies are
needed to elucidate the true impact of some of the mutational
patterns we found in the efficacy of raltegravir.
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